“…Convincing evidence has shown that SOX4, as the direct transcription target of Smad2 and Smad3 downstream of TGFβ, plays a master role in TGFβ-induced EMT, invasion, and metastasis of tumors [ 51 , 52 ]. In HCC, the SOX4 expression is remarkably increased in tumor tissues, especially in metastatic and recurrent HCC samples [ 53 , 54 , 55 , 56 , 57 , 58 , 59 ]. The overexpressed SOX4 is positively associated with higher intratumoral microvessel density, distant metastasis, and poor survival of HCC cases, which provides a potential diagnostic and prognostic marker for HCC [ 56 , 57 , 58 , 59 ].…”